Spotlight on chronic lymphocytic leukemia: a Pharma Matters report.
London, United Kingdom. In Drugs Today (barc), Jul 2014
Imbruvica (ibrutinib), an oral first-in-class Bruton's tyrosine kinase inhibitor, recently entered the market following accelerated approval in the relapsed/refractory setting, but long-term survival data are currently immature.
[Kinase inhibitors against hematological malignancies].
In Nihon Rinsho, Jun 2014
As for AML and lymphoid malignancies, many kinase inhibitors targeting FLT3, BTK and aurora-A are on early and late clinical trials, and a number of promising drugs including ibrutinib are picked up for further evaluation.